Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Clinical trial NCT04256707 · COMPLETED

Trial details

NCT number: NCT04256707
Sponsor: Karyopharm Therapeutics Inc
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Carcinoma (NSCLC)Colorectal Cancer (CRC)Other Solid Tumors

Start date: 2020-01-14
Primary completion: 2024-07-31
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.